Document:

sanofi_biontech-amendedr

CONFIDENTIAL  Execution version  AMENDED & RESTATED  DEVELOPMENT AGREEMENT   This amended and restated development agreement (this Agreement) is effective as of  July 7, 2021 (the Effective Amendment Date) and entered into by and between Sanofi, having  a place of business at 54, rue La Boétie, 75008 Paris, France (Sanofi), and BioNTech RNA  Pharmaceuticals GmbH, having a place of business at An der Goldgrube 12, 55131 Mainz,  Germany (Biontech). Sanofi and Biontech shall each individually be referred to herein as a  Party, and shall be referred to together as the Parties.  RECITALS  A. On November 2 nd, 2015, as amended by an amendment letter dated December 14th, 2017, the Parties entered into a Collaboration and License Agreement (the  License Agreement) with the desire to collaborate in the research, development and  commercialization of RNA-based therapeutics for the treatment of cancer.  B. Under the License Agreement, a Mixture named Licensed Product #1 (as further defined below) has been approved by the Joint Steering Committee as a Licensed Product  Candidate in accordance with Section 2.8 of the License Agreement.   C. On [***], Sanofi selected Licensed Product #1 as the first Licensed Product for further Development and Commercialization in accordance with Section 2.9 of the License  Agreement and on [***] Biontech exercised its option to co-Develop and to co-Commercialize  Licensed Product #1 in the Field in the Biontech Territory in accordance with Section 4.1 of the  License Agreement.  D. The Parties entered into a Development Agreement (the “Original Agreement”) on March 29, 2018 in order to jointly Develop Licensed Product #1 in the Field.    E. The Parties hereby wish to amend and restate the Original Agreement in order to address intellectual property rights relating to [***] formulations as well as the  corresponding license grants. This Agreement constitutes the Development agreement with  respect to Licensed Product #1 under Section 4.1.1 of the License Agreement.  NOW, THEREFORE, in consideration of the foregoing premises and the mutual  covenants set forth below, the Parties hereby agree as follows:  1. Definitions. Capitalized terms used in this Agreement shall have the meanings as defined herein,  provided that capitalized terms which are used but not defined herein shall have the meanings  ascribed to them in the License Agreement.  1.1 Additional Co-Development Costs is defined in Section 6.3.4.  1.2 Approved Co-Development Third Party means a Third Party  subcontractor or other Third Party engaged by a Party to perform or assist with any of such  Party’s obligations under this Agreement, and which (a) is listed in Schedule A; or (b) has been  approved by the Joint Project Team under Section 6.2(h).   1.3 Binding Budget is defined in Section 3.3.1.  THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN  EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE  COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Exhibit 4.57 

 

Amended & Restated Development Agreement  Execution version  2  1.4 Biontech Co-Development Know-how is defined in Section 4.1.2.  1.5 Biontech Co-Development Patents is defined in Section 4.2.2.  1.6 Biontech Co-Development Technology means the Biontech Co- Development Know-how and the Biontech Collaboration Patents.  1.7 Budget means a rolling [***] budget set out in the  Development Plan with respect to the forecasted Shared Development Costs to be incurred by  each Party during each such Calendar Year during the Term, as amended or updated from time  to time by the Joint Project Team or the Joint Steering Committee (as the case may be) in  accordance with this Agreement.  1.8 Calendar Quarter means each successive period of three (3) calendar  months commencing on January 1, April 1, July 1 and October 1, except that the last Calendar  Quarter shall end on the last day of the Term.  1.9 Calendar Year means each successive period of twelve (12) calendar  months commencing on January 1, except that the last Calendar Year shall end on the last day  of the Term.  1.10 Clinical Data means [***], results and analyses [***] generated by or  on behalf of either Party or at either Party’s direction, or by or on behalf of the Parties  together or at their direction, in the course of the performance of the clinical trials under the  Development Plan.  1.11 Clinical Supply Agreement means the Clinical Development and  Supply Agreement between the Parties, effective as of October 4th, 2017.  1.12 CMC means “Chemistry, Manufacturing, and Controls” as such term of  art is used in the pharmaceutical industry.    1.13 CMC Activities means the activities with respect to Licensed Product #1  set out in the CMC Development Plan (or, for the purposes of Section 2.8.3, 2.8.4 and 2.8.5,  the activities with respect to Licensed Product #1 proposed to be included in the CMC  Development Plan).    1.14 CMC Development Plan means the development plan setting out the  CMC and manufacturing process development activities with respect to Licensed Product #1  as set out in Schedule D, and amended by the Joint Manufacturing Committee or the Joint  Steering Committee (as applicable) from time to time pursuant to Section 2.8.5.    1.15 CMC Know-how means the Know-how made, conceived or first  reduced to practice by or on behalf of either Party (or its Affiliates), or jointly by or on behalf  of the Parties (or their Affiliates), in the conduct of the activities under the CMC Development  Plan.  1.16 CMC Patents is defined in Section 4.2.2.  1.17 CMC Technology means the CMC Know-how and CMC Patents.  1.18 Co-Development Activities means the Development and other activities  with respect to the Licensed Product #1 in the Field as specified in or reasonably contemplated  

 

Amended & Restated Development Agreement  Execution version  3  by the Development Plan.  For the avoidance of doubt, Co-Development Activities exclude the  activities set out in the CMC Development Plan.    1.19 Co-Development Background Technology means, with respect to a  Party, all Intellectual Property Rights over which such Party has gained Control outside of the  scope of the collaboration under the License Agreement (including the activities under this  Agreement) during the Term, excluding any Background Technology.  1.20 Co-Development Personnel means the individuals engaged by a Party  performing Co-Development Activities, including any of the foregoing who are Project  Managers, members of the Joint Steering Committee, Joint Project Team, regulatory personnel,  quality assurance personnel, quality control personnel, research personnel, and development  personnel.   1.21 Co-Development Report is defined in Section 2.5.  1.22 Co-Development Records is defined in Section 2.6.1.  1.23 CPI means the Consumer Price Index – Urban Wage Earners and  Clerical Workers, U.S. City Average, All Items, 1982-84 = 100, published by the United States  Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the  United States.  1.24 Development Plan means the development plan set out in Schedule C  and amended or updated from time to time (through the proposal of such amendments or  updates to the Joint Steering Committee and the approval of such amendments or updates by  the Joint Steering Committee), setting forth in reasonable detail: (i) the clinical Development  strategy, (ii) the objectives for Development activities and market access, (iii) Development  activities, including clinical trials and regulatory filings, (iv) the definition of countries or  regions in which clinical trials shall be conducted, (v) an allocation of each Party’s  responsibilities and (vi) timelines and the associated Budget, in each case (i) to (vi), with respect  to Licensed Product #1 in the Field intended for approval or Commercialization in the Biontech  Territory.  For the avoidance of doubt, the Development Plan excludes the CMC Development  Plan.  1.25 Effective Amendment Date is defined in the introductory paragraph of  this Agreement.  1.26 Excluded Clinical Trial Costs is defined in Section 1.52.  1.27 Formulation Know-how means:  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Amended & Restated Development Agreement  Execution version  4  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] v1.28 Formulation Patents [***] 1.29 Formulation Technology means the Formulation Know-how and  Formulation Patents.   1.30 FTE Costs means the cost of the Co-Development Personnel incurred  by either Party, calculated at the FTE Rate multiplied by the applicable number of FTEs of Co- Development Personnel of such Party (on the basis of actual hours worked by such Co- Development Personnel on the Co-Development Activities or the activities in support thereof).  For the avoidance of doubt, when calculating FTE Costs, any full-time employee who works  more than [***] hours over the course of a twelve (12) month period shall count as one (1)  FTE.    1.31 FTE Rate means [***] per FTE. Such rate shall be automatically  adjusted on an annual basis in accordance with Section 2.2.3.   1.32 including means “including without limitation” (and include means  “include without limitation”).  

 

Amended & Restated Development Agreement  Execution version  5  1.33 Initiation means, with respect to a clinical trial, the first dosing of a  human subject with Licensed Product #1 in such clinical trial.  1.34 Joint Financial Committee is defined in Section 6.5.1.  1.35 Joint Manufacturing Committee means the joint manufacturing  committee established under the Clinical Supply Agreement.  1.36 Joint Patent Committee is defined in Section 6.5  1.37 Joint Project Team is defined in Section 6.2.  1.38 License Agreement is defined in the preamble.  1.39 Licensed Product #1 means (a) the Mixture specified in Schedule B; or  (b) any modified version of such Mixture as proposed by the Joint Project Team pursuant to Section 6.2(f) and approved by the Joint Steering Committee. For the avoidance of doubt, Licensed Product #1 includes any formulation in the Field of any Mixture described in (a) and (b). 1.40 Patent Documentation is defined in Section 4.9.  1.41 Prosecution and Maintenance (including variations such as Prosecute  and Maintain) means, with respect to a Patent Right, the preparation, filing, prosecution and  maintenance of such Patent Right, including paying all maintenance and/or governmental fees  to maintain such Patent Right in force, and requests for patent term extensions, supplementary  protection certificates, and the like with respect to such Patent Right, together with the conduct  of reissue proceedings, derivation proceedings, the defense of oppositions, ex parte  reexaminations, inter partes reviews, post-grant reviews, and other similar proceedings with  respect to such Patent Right.  1.42 Overspent Costs is defined in Section 3.3.2.  1.43 Overspent Costs Notice is defined in Section 3.3.2.  1.44 Project Manager is defined in Section 6.1.  1.45 Regulatory Documentation means all (a) marketing authorizations or  registrations or any other approval, registration or authorization which is granted or accepted  by a Regulatory Authority in a country in the Biontech Territory that are required for the  Development, Manufacture or Commercialization of a Licensed Product #1 in the Field in such  country, and all filings and submissions to a Regulatory Authority with respect to any of the  foregoing; (b) correspondence, reports and other filings submitted to or received from  Regulatory Authorities (including minutes and official contact reports relating to any  communications with any Regulatory Authority) in order to Develop, Manufacture or  Commercialize a Licensed Product #1 in the Field in the Biontech Territory.   1.46 Right of Reference means the non-exclusive right to cross reference,  copy, incorporate by reference or rely upon any Clinical Data solely for the purposes of  obtaining or maintaining Marketing Approval for a pharmaceutical product, including (1) a  “Right of Reference or Use” as that term is defined in 21 C.F.R. §314.3(b) in the United States,  (2) any analogous procedures with respect to biologics or BLAs in the United States and (3) any equivalents thereof outside the United States. 

 

Amended & Restated Development Agreement  Execution version  6  1.47 SDEA is defined in Section 7.2.  1.48 Sanofi CMC Technology means: (a) the CMC Know-how which is  generated by or on behalf of Sanofi (or its Affiliates) or jointly by or on behalf of the Parties  (or their Affiliates) in the conduct of the CMC Activities agreed by the Joint Manufacturing  Committee (or, if the Joint Manufacturing Committee cannot agree on such matters, approved  by the Joint Steering Committee pursuant to Section 6.3.2(c)) for performance by Sanofi under  the CMC Development Plan; and (b) the CMC Patents claiming or covering such CMC Know- how.  1.49 Sanofi Co-Development Know-how is defined in Section 4.1.1.  1.50 Sanofi Co-Development Patents is defined in Section 4.2.1.  1.51 Sanofi Co-Development Technology means the Sanofi Co- Development Patents and the Sanofi Co-Development Know-how.  1.52 Shared Development Costs means the out-of-pocket costs and expenses  and FTE Costs incurred by either Party or its Affiliate, in each case which are: (1) specifically  identifiable to, or reasonably allocable to, any Co-Development Activity [***]; and (2)  calculated in accordance with IFRS consistently applied, including (to the extent they come  within the foregoing):   (a) the costs and expenses associated with the conduct of non- clinical studies [***];  (b) the costs and expenses associated with the conduct of clinical trials [***];   (c) the costs and expenses associated with the preparation, filing, submission, obtaining or maintenance (as applicable) of Regulatory Documentation with  respect to any Licensed Product #1 in the Field; and  (d) the costs and expenses with respect to Approved Co- Development Third Parties engaged in the performance of such Co-Development Activity.   Excluded Clinical Trial Costs  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Amended & Restated Development Agreement  Execution version  7  [***]shall be referred to as the Excluded Clinical Trial Costs.  Notwithstanding the foregoing, “Shared Development Costs” shall exclude [***] 1.53 Shared Formulation Patent Costs is defined in Section 4.10.2.  1.54 Tax or Taxes means any federal, provincial, territorial, state, municipal,  local, foreign or other taxes and other charges in the nature of a tax.  1.55 Term is defined in Section 9.1.  1.56 VAT is defined in Section 3.7.3.  1.57 Withholding Tax or Withholding Taxes is defined in Section 3.7.2.  2. Development of Licensed Product #1. 2.1 Development Activities Generally.   2.1.1 Each Party shall:  (a) perform the Co-Development Activities allocated to such Party under the Development Plan in accordance with the terms of this Agreement;  (b)  contribute and commit the required resources and use Commercially Reasonable Efforts to meet the objectives set forth in the Development Plan;  and  (c) perform its obligations under this Agreement in accordance with the Applicable Law.    2.1.2 The Development Plan in force at the Effective Amendment  Date is set out in Schedule C.  No later than [***] (or such other period as agreed by the Joint  Steering Committee under Section 6.3.2(f)) prior to the end of each Calendar Year,  commencing [***], the Joint Project Team shall review the Development Plan and propose  any updates to the Development Plan to the Joint Steering Committee pursuant to  

 

Amended & Restated Development Agreement  Execution version  8  Section 6.2(c), such that the Joint Steering Committee can review and approve such  proposed updated Development Plan pursuant to Section 6.3.2(b) no later than [***] days  prior to the end of such Calendar Year.   In addition, from time to time, the Joint Project  Team shall review any proposal from either Party to amend the Development Plan, for  proposal to the Joint Steering Committee pursuant to Section 6.2(c).  Upon approval of the  Joint Steering Committee of any such update or amendment, the Development Plan shall be  deemed to be amended to incorporate such update or amendment.  2.1.3 For clarity, the Development Plan, and accordingly, the Co- Development Activities, shall exclude any CMC Activities conducted under the CMC  Development Plan.   2.2 Allocation of Resources/Subcontracting.  2.2.1  Each Party agrees to primarily use its or its Affiliates’ internal  resources and capacities to fulfil such Party’s respective obligations under the Development  Plan. Each Party shall use Commercially Reasonable Efforts to minimize the delegation of its  obligations hereunder to a Third Party subcontractor (including contract research  organizations).   2.2.2 Each Party may subcontract any of its obligations under this  Agreement to any of its Affiliates or one or more Approved Co-Development Third Parties,  provided that: (i) none of the rights of the other Party are diminished or are otherwise adversely  affected as a result of such subcontracting and (ii) the Approved Co-Development Third Party  undertakes in writing all obligations of confidentiality and non-use regarding both Parties’  Confidential Information which are substantially the same as those undertaken by the Parties  under the License Agreement.  In the event that a Party performs one or more of its obligations  under this Agreement through any such Affiliate or Approved Co-Development Third Party,  then such Party shall at all times be responsible for the performance by such Affiliate or  Approved Co-Development Third Party of such Party’s obligations hereunder.   2.2.3 All internal Co-Development Personnel of each Party (or its  Affiliates) shall be expressed in terms of FTEs. The FTE Rate shall be adjusted on an annual  basis, the first adjustment shall be on January 1, 2019 and thereafter each adjustment shall be  on January 1 of each succeeding Calendar Year.  Each such adjustment shall be calculated by  increasing the FTE Rate as of December 31, 2018 by the percentage increase in the CPI as of  December 31 of the then most recently ended Calendar Year over the level of the CPI on  December 31, 2018.  2.3 Conduct of Clinical Trials. Sanofi shall act as the sponsor of any clinical  trial conducted pursuant to the Development Plan, provided that Sanofi shall consider in good  faith whether to use Biontech’s resources in regions where such internal resources are available  [***] and whether in certain circumstances Biontech shall be the co-sponsor or sponsor of  selected clinical trials. The Party acting as sponsor (or co-sponsor, as applicable) shall  ensure that any such clinical trial (for which it is sponsor (or co-sponsor, as applicable)) is  performed in accordance with this Agreement, the applicable protocol and Applicable Law,  and the other Party shall provide such Party with any assistance as reasonably requested by  such Party, in order for such Party to fulfil its obligations as sponsor (or co-sponsor) of such  clinical trial. Each Party shall mention or list the other Party as collaborator (e.g. “in  collaboration with BioNTech RNA Pharmaceuticals GmbH” or “in collaboration with Sanofi”,  as applicable)) (and the other Party hereby agrees to such mention or listing) in the relevant  clinical trial databases and registers (e.g. clinicaltrials.gov (or equivalent)), in public materials  

 

Amended & Restated Development Agreement  Execution version  9  published by such Party in relation to all clinical trials conducted pursuant to the Development  Plan and, to the extent reasonably practicable, on labels of vials used in such clinical trials, as  well as when either Party formally presents the Development program under this Agreement at  conferences, provided that, prior to any such mention, listing or publication the Parties have  agreed in writing the form of information that can be used in such mentions, listings or  publications, and all mentions, listings and publications of a Party as collaborator under this  Section 2.3 shall be made in all cases in a manner and to the extent consistent with Applicable  Law and such agreed form of information.   2.4 Biomarker Execution. [***] 2.5 Reporting. Each Party shall keep the other Party reasonably informed as  to its progress, results (including the development of any technology or invention), status and  plans with respect to the Co-Development Activities performed by or on behalf of such Party  through the provision of periodic, informal oral reports to the other Party’s Project Manager.   Without limiting the foregoing, each Party shall provide to the other Party a [***] written  report (the Co-Development Report) delivered no later than [***] following the end of each  [***], such written report shall set out detailed particulars of the following items: (a) the Co- Development Activities performed by such Party during such [***]; (b) the data, results  and other Intellectual Property Rights made, conceived and first reduced to practice in the  conduct of such Co-Development Activities by or on behalf of such Party; (c) the status of  preparation for the planned Co-Development Activities to be performed in the upcoming  [***] and the status of such activities; and (d) any other relevant information determined by  the Joint Project Team to be included in such report pursuant to Section 6.2(i).   2.6 Maintenance of Records.   2.6.1 During the Term and for a period of at least [***] after the  Term (or, if longer, a period required by Applicable Law), each Party shall maintain records  reflecting the work done and the results achieved in its performance of the Development Plan  (the Co-Development Records), such records shall be in a reasonable level of detail customary  for companies engaged in pharmaceutical research.  Without limiting the foregoing, such  records shall be in sufficient detail and in good scientific manner appropriate for patent and  regulatory purposes in compliance with Applicable Law.  2.6.2 Each Party shall make its Co-Development Records available for  inspection by the other Party or its representative, during normal business hours and upon  reasonable notice, upon reasonable written request of the other Party. Upon request by each  Party, the other Party shall deliver to the requesting Party copies of all its Co-Development  Records (which may include copies in an electronic format readily accessible by the requesting  Party), provided that the requesting Party shall reimburse the reasonable and documented out- of-pocket costs incurred by the other Party in connection with the preparation and delivery of  such copies.  Each Party shall not be obliged to: (a) provide the other Party with access to its  Co-Development Records or (b) deliver to the other Party copies of its Co-Development  Records, in each case (a) and (b), more than [***].   2.7 Ownership of Clinical Data. Sanofi shall exclusively own all Clinical  Data, [***]  

 

Amended & Restated Development Agreement  Execution version  10 [***] Each Party acknowledges and agrees that Section 4.1.2 of the License Agreement shall  not apply to such Clinical Data.   2.8 Manufacturing and Clinical Supply of Licensed Product #1.  2.8.1 The Parties’ respective responsibilities relating to the  Manufacturing and supply of Licensed Product #1 to be used for Phase I Clinical Trials and  Phase II Clinical Trials are set forth in the Clinical Supply Agreement and the License  Agreement. If the Joint Steering Committee approves any modification to the Licensed Product  #1 set out in Schedule B pursuant to Section 6.3.2(d), at Sanofi’s request, the Parties shall  promptly update Appendix 1 of the Clinical Supply Agreement, such that the Licensed Product  #1 incorporating such modification shall constitute a Drug Product under the Clinical Supply  Agreement.   2.8.2 Biontech shall: (a) subject to Section 2.8.3, be responsible for the  performance of all CMC Activities with respect to Licensed Product #1 under the CMC  Development Plan; (b) perform the CMC Activities allocated to Biontech under the CMC  Development Plan in accordance with the terms of this Agreement, and (c) contribute and  commit the required resources and use Commercially Reasonable Efforts to meet the objectives  set forth in the CMC Development Plan.   2.8.3 If either Party wishes Sanofi to perform any CMC Activities with  respect to Licensed Product #1, such Party shall propose to the Joint Manufacturing Committee  an update to the CMC Development Plan reflecting such CMC Activities to be performed by  Sanofi, and Sanofi may perform such CMC Activities if agreed by the Joint Manufacturing  Committee or, if the Joint Manufacturing Committee cannot reach agreement on such matter,  upon the approval by the Joint Steering Committee pursuant to Section 6.3.2(c) of such update  to the CMC Development Plan.    2.8.4 The initial version of the CMC Development Plan is set out in  Schedule D.  Thereafter, the Joint Manufacturing Committee shall discuss and approve any  amendments to the CMC Development Plan proposed by either Party under Section 2.8.5(a)  (provided, with respect to any proposed amendments to the CMC Development Plan to provide  for Sanofi’s performance of any CMC Activities, if the Joint Manufacturing Committee cannot  agree on such matters, the Joint Steering Committee shall decide whether Sanofi may perform  such CMC Activities pursuant to Section 6.3.2(c)). Biontech shall keep the Joint Manufacturing  Committee fully informed as to its progress, results (including the development of any  technology or inventions), status and plans for performing and implementing the CMC  Development Plan, including by periodic, informal oral reports to the Joint Manufacturing  Committee, and by providing a quarterly report to the Joint Manufacturing Committee with  respect to CMC Activities performed under the CMC Development Plan delivered no later than  [***] following the end of every Calendar Quarter, such written report shall set out detailed  particulars of the following items: (a) the CMC Activities performed under the CMC  Development Plan during such [***]; (b) the data, results and other Intellectual Property  Rights made, conceived and first reduced to practice in the performance of such CMC  Activities; (c) the status of preparation for the planned CMC Activities to be performed  under the CMC Development Plan in the upcoming [***] and the status of such CMC  

 

Amended & Restated Development Agreement  Execution version  11 Activities; and (d) any other relevant information determined by the Joint Manufacturing  Committee to be included in such report pursuant to Section 2.8.5(b).    2.8.5  The Joint Manufacturing Committee shall be responsible for  discussing and approving: (a) any amendments to the CMC Development Plan as proposed by  either Party; and (b) the information to be included in the quarterly written reports described in  Section 2.8.4. If the members of the Joint Manufacturing Committee cannot agree on such  matters, notwithstanding anything to the contrary in Section 3.3.6 of the License Agreement  and Sections 9.4 and 9.5 of the Clinical Supply Agreement: (i) with respect to any proposed  amendment or update to the CMC Development Plan to provide for Sanofi’s performance of  any CMC Activities as described in Section 2.8.4, such matter shall be referred to the Joint  Steering Committee for decision under Section 6.3.2(c); and (ii) with respect to any other  matter, Sanofi shall have the deciding vote, and the third sentence of Section 9.5 of the Clinical  Supply Agreement shall not apply with respect to such matter.   2.8.6 For the avoidance of doubt, the Manufacture and supply of any  Licensed Product #1 for use in Phase III Clinical Trials pursuant to the Development Plan are  subject to Sections 3.3.3 to 3.3.6 of the License Agreement.  3. Development Costs. 3.1 Development Costs related to the Biontech Territory. All Shared  Development Costs shall be shared between the Parties pursuant to the following  scheme:   [***] [***]  [***] [***]  3.2 Development Costs not related to the Biontech Territory. Sanofi shall  remain solely responsible [***]  3.3 Budget.   3.3.1 Annual Development Plan Budget.  (a) The Budget shall include particulars of the Shared Development Costs which each Party is reasonably expected to incur with respect to its Co-Development  Activities during [***] period. Each Party acknowledges and agrees that [***], the Binding  Budget).  The initial Binding Budget is set out in Schedule C to this Agreement.  Thereafter, the Budget shall be updated in accordance with Section 3.3.1(b).    

 

Amended & Restated Development Agreement  Execution version  12 (b) No later than [***] (or such other period as agreed by the Joint Project Team under Section 6.2(p)) prior to the end of [***], the Parties’  respective Joint Project Team representatives shall in good faith discuss the Budget: (i) if  such Calendar Year is [***] or [***], for the following [***] (3) Calendar Year period  (excluding the Calendar Year(s) comprising the then-current Binding Budget); or (ii) if such  Calendar Year is [***] or any Calendar Year thereafter, [***], in each case (i) and (ii),  pursuant to Section 6.2(d), and shall submit a proposed Budget to the Joint Financial  Committee for review and comments.  The Joint Project Team shall consider any  comments from Joint Financial Committee with respect to such proposed Budget and may  (but shall not be required to) amend such proposed Budget accordingly.  Thereafter, the  Joint Project Team shall submit the proposed Budget to the Joint Steering Committee  for review and approval under Section 6.3.2(b), such that such proposed Budget shall be  approved by the Joint Steering Committee no later than [***] prior to the end of such  Calendar Year.  In addition, the Joint Project Team may discuss any amendment to the  Binding Budget pursuant to Section 6.2(d) and propose such amendment to the Joint  Steering Committee for approval under Section 6.3.2(c).  Notwithstanding the foregoing,  from time to time, the Joint Project Team may approve any amendment to the Binding  Budget with respect to the then-current Calendar Year under Section 6.2(e) without having  to propose such amendment to the Joint Steering Committee, if the proposed amended  Binding Budget will not deviate by [***] or more from the Binding Budget for such  Calendar Year as of the first day of such Calendar Year. 3.3.2 Overspent Costs.   (a) Each Party shall promptly inform the other Party if it reasonably determines that it will or is likely to incur, or has incurred, any Shared Development Costs  during any Calendar Year above [***] of the aggregate Shared Development Costs allocated  to such Party in the Binding Budget with respect to such Calendar Year (the Overspent Costs),  such notice shall set out the amount of estimated or actual Overspent Costs in question (the  Overspent Costs Notice).    (b) Upon the submission of an Overspent Costs Notice from one Party to the other Party under Section 3.3.2(a), either Party may escalate the matter to the Joint  Steering Committee. Upon such escalation, the Joint Steering Committee shall promptly (and  in any event, no later than [***] after such escalation) discuss and decide whether the  Binding Budget shall be amended.   (c) For the avoidance of doubt, if the Joint Steering Committee has approved an amendment to the Binding Budget for the relevant Calendar Year reflecting the  Overspent Costs in question, such Overspent Costs shall continue to constitute Shared  Development Costs.  (d) If the Joint Steering Committee has not approved an amendment to the Binding Budget for the relevant Calendar Year reflecting the Overspent Costs in  question, then such Overspent Costs shall not be considered Shared Development Costs.    3.3.3 Reporting. Shared Development Costs and the Excluded Clinical  Trial Costs shall initially be borne by the Party (or its Affiliate) incurring such cost or expense.  Each Party shall report to the other Party, [***], the Shared Development Costs and any  Excluded Clinical Trial Costs incurred by such Party (or its Affiliate) during [***]. Such  report shall include  

 

Amended & Restated Development Agreement  Execution version  13 the details necessary to enable the receiving Party to compare the reported Shared Development  Costs against the applicable Budget, including specifying in reasonable detail all Shared  Development Costs and any Excluded Clinical Trial Costs incurred by such Party (or its  Affiliate) during such [***], whereby all FTE Costs and out-of-pocket costs or expenses  with respect to Shared Development Costs shall be allocated to the extent possible to a specific  activity under the Development Plan. The Parties shall seek to resolve any questions related to  such reports within [***] following receipt by each Party of the other Party’s report  hereunder.   3.3.4 Invoicing and Reconciliation of Shared Development Costs.  Following the end of each [***]: (1) if Sanofi (or its Affiliates), but not Biontech (or its  Affiliates), have incurred Shared Development Costs with respect to such Calendar  Quarter, then Sanofi may submit an invoice to Biontech with respect to Biontech’s share of the  Shared Development Costs for such [***] in accordance with the scheme set out in Section  3.1; and (2) otherwise, the Shared Development Costs borne by each Party or its Affiliate  with respect to such [***] shall be reported and reconciled as follows:    (a) no later than [***] days after the end of such [***] (provided that, Sanofi shall not be obliged to observe such timeframe if Biontech fails to provide  the report described in, and within the [***] period set out in, Section 3.3.3), Sanofi shall  submit to Biontech a proposed reconciliation report, setting out the particulars with  respect to the reconciliation of the Shared Development Costs incurred by each Party or its  Affiliate with respect to such [***].  For the purposes of such reconciliation, the Shared  Development Costs incurred by each Party or its Affiliate shall be shared between the Parties  in accordance with the scheme set out in Section 3.1;  (b) if Biontech disagrees with such reconciliation report, Biontech  may, no later than [***] after Sanofi’s submission of the proposed reconciliation report to  Biontech, request the Joint Financial Committee to review such report under Section 6.5.2(a);   (c) (1) upon any confirmation by Biontech to Sanofi of its  acceptance of such reconciliation report; (2) if Biontech has not requested the Joint Financial  Committee to review and discuss such reconciliation report within the [***] period  described in clause (b) above,  upon the expiry of such [***] period; or (3) if Biontech has  requested the Joint Financial Committee to review such reconciliation report within such [***]  period, upon approval of such reconciliation report  by the Joint Financial Committee:   (i) if the Shared Development Costs incurred by Biontech or  its Affiliate in such [***] is less than its agreed share of Shared Development Costs during such  [***], Sanofi or its Affiliate shall deliver an invoice to Biontech for any amounts due to  Sanofi as a result of such reconciliation;  (ii) if the Shared Development Costs incurred by Sanofi or  its Affiliate in such [***] is less than its agreed share of Shared Development Costs during such  [***], Sanofi shall notify Biontech that Biontech should issue an invoice to Sanofi for any  amounts due to Biontech as a result of such reconciliation,  (d) each Party shall pay the relevant reconciliation payment to the  respective other Party within [***] days following receipt of the respective invoice from  the other Party.  

 

Amended & Restated Development Agreement  Execution version  14 3.4 Records and Audit Rights. Each Party shall keep complete and accurate  records for all of its Shared Development Costs, including the details of the FTEs allocated to  the performance of its Co-Development Activities based on the actual hours of work spent on  such performance. Each Party shall make such records available to the other Party upon request.  For the avoidance of doubt, such records shall constitute the records reasonably necessary to  verify the accuracy of the costs associated to the applicable Party’s Development activities  under Section 4.5 of the License Agreement, and the provisions of Section 4.5 of the License  Agreement shall apply with respect to such records accordingly.  3.5 Payment. All payments to be made by one Party to the other Party under  this Agreement shall be made in Euros by bank wire transfer without deduction for wire transfer  fees in immediately available funds to such bank account designated in writing by the receiving  Party to the paying Party from time to time.  3.6 Accounting and Currency.  Shared Development Costs and Excluded  Clinical Trial Costs shall be calculated, recorded and reported under this Agreement in  accordance with the last updated IFRS and in Euros.  In the case of Shared Development Costs  and Excluded Clinical Trial Costs which are initially incurred in a currency other than Euros,  exchange conversion of such amounts into Euros shall be made on a [***] basis and shall  be made consistent with the incurring Party’s normal practices used to prepare its audited  financial statements for internal and external reporting purposes, which uses a widely accepted  source of published exchange rates.   3.7 Taxes.   3.7.1 Each Party shall be solely responsible for the payment of all  Taxes imposed on such Party’s income arising directly or indirectly from the activities of the  Parties under this Agreement. [***]                                      3.7.2 [***] 3.7.3 All payments between the Parties under this Agreement are  exclusive of applicable statutory value added tax (VAT), if any, which shall be listed separately  on each invoice. [***]  

 

Amended & Restated Development Agreement  Execution version  15 [***] 4. Intellectual Property and Licensed Products. 4.1 Each Party acknowledges and agrees that: 4.1.1 Sanofi shall solely own all Know-how made, conceived or first  reduced to practice:   (a) by or on behalf of Biontech (or its Affiliates) or jointly by or on behalf of the Parties (or their Affiliates) in the conduct of the Co-Development Activities, to  the extent such Know-how: (i) is necessary or useful for Developing, Commercializing or  otherwise using Licensed Product #1; (ii) if patented, would encompass an activity or  composition that is necessary or useful for the Development, Commercialization or other use  of Licensed Product #1; or (iii) is otherwise related to Licensed Product #1. [***] (b) by or on behalf of Sanofi (or its Affiliates) in the conduct of the Co-Development Activities; and   (c) by or on behalf of either Party (or its Affiliates) or jointly by or on behalf of the Parties (or their Affiliates) in the conduct of activities in connection with the  preparation of the clinical trials with respect to Licensed Product #1 [***] that were conducted  before the effective date of the Original Agreement,   together (a), (b) and (c), the Sanofi Co-Development Know-how.   4.1.2 Biontech shall solely own:   (a) all Know-how made, conceived or first reduced to practice by or on behalf of Biontech (or its Affiliates) in the conduct of the Co-Development Activities to the  extent such Know-how does not constitute Sanofi Co-Development Know-how (the Biontech  Co-Development Know-how); and   (b) all CMC Know-how; and (c) all Formulation Know-how. 4.2 As between the Parties:    4.2.1 Sanofi shall: (a) have the exclusive right (but not the obligation),  at its sole expense and sole discretion, to control the Prosecution and Maintenance and  enforcement of all Patent Rights claiming or otherwise covering any Sanofi Co-Development  Know-how (the Sanofi Co-Development Patents) and (b) solely own the Sanofi Co- Development Patents; and  

 

Amended & Restated Development Agreement  Execution version  16 4.2.2 Biontech shall: (a) have the exclusive right (but not the  obligation), at its sole expense and sole discretion, to control the Prosecution and Maintenance  and enforcement of all Patent Rights claiming or otherwise covering any Biontech Co- Development Know-how (the Biontech Co-Development Patents) and all Patent Rights  claiming or otherwise covering any CMC Know-how (the CMC Patents) and (b) solely own  the Biontech Co-Development Patents, the CMC Patents, and the Formulation Patents.   For the avoidance of doubt, for the purposes of interpretation of Section 1.48(b) and  this Section 4.2, Sanofi Co-Development Know-how, Biontech Co-Development Know-how,  CMC Know-how, and Formulation Know-how shall not cease to be Know-how to the extent  it is disclosed or claimed by a Sanofi Co-Development Patent, Biontech Co-Development  Patent, CMC Patent, or Formulation Patent (as applicable).  4.2.3 Sanofi shall have the exclusive right (but not the obligation), at  its sole discretion, to control the Prosecution and Maintenance and enforcement of all  Formulation Patents to the extent such Formulation Patents contain:  (i) [***] (ii) [***] (iii) [***] or (iv) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]  

 

Amended & Restated Development Agreement  Execution version  17 [***] [***] [***] [***] 4.3 For the purposes of Section 7.3.2(b)(ii) (Co-Development and Co- Commercial License (Biontech Option Product) to Biontech) of the License Agreement only,  Sanofi Co-Development Technology shall constitute Sanofi Technology).    4.4 For the purposes of Section 7.3.1(b)(iii) (Co-Development and Co- Commercial License (Sanofi Option Product) to Sanofi) of the License Agreement, Biontech  Co-Development Technology, CMC Technology, and Formulation Technology shall constitute  Biontech Technology.    4.5 For the purposes of Section 1.88 (Royalty Term) of the License  Agreement only, a Formulation Patent shall constitute a Licensed Product Patent.   4.6 Sanofi hereby grants to Biontech:  4.6.1 an exclusive, non-transferable (except through assignment of  this Agreement pursuant to Section 13.4 of the License Agreement as incorporated into this  Agreement under Section 11.4), worldwide license, with the right to sublicense (subject to  Section 4.15), under the Sanofi Co-Development Technology to Develop, have Developed,  make, have made, Commercialize and have Commercialized Licensed Products outside of the  Field and Discarded Mixtures;   4.6.2 an irrevocable, perpetual, royalty-free, fully paid-up, non- exclusive, non-transferable (except through assignment of this Agreement pursuant to Section  13.4 of the License Agreement as incorporated into this Agreement under Section 11.4),  worldwide license, with the right to sublicense (subject to Section 4.15), under the Sanofi Co- Development Technology to research, have researched, Develop, have Developed, make, have  made, Commercialize and have Commercialized  any product in and outside the Field  (excluding any Licensed Product and any Discarded Mixture); and  4.6.3 a non-exclusive, non-transferable (except through assignment of  this Agreement pursuant to Section 13.4 of the License Agreement as incorporated into this  Agreement under Section 11.4), worldwide, royalty-free license, with the right to sublicense  (subject to Section 4.15), under the Co-Development Background Technology of Sanofi to the  extent required by Biontech for the co-Development and/or the co-Commercialization of  Licensed Product #1 in accordance with this Agreement and/or Commercialization agreement  concluded in relation to Licensed Product #1 under Section 4.1.3 of the License Agreement.   [***] [***] [***] [***] [***] [***] 

 

Amended & Restated Development Agreement  Execution version  18 [***]    4.7 Biontech hereby grants to Sanofi:  4.7.1 an exclusive, non-transferable (except through assignment of  this Agreement pursuant to Section 13.4 of the License Agreement as incorporated into this  Agreement under Section 11.4), worldwide license, with the right to sublicense (subject to  Section 4.15), under the Biontech Co-Development Technology and the CMC Technology to  Develop, have Developed, make, have made, Commercialize and have Commercialized  Licensed Products in the Field;   4.7.2 an irrevocable, perpetual, royalty-free, fully paid-up, non- exclusive, non-transferable (except through assignment of this Agreement pursuant to Section  13.4 of the License Agreement as incorporated into this Agreement under Section 11.4),  worldwide license, with the right to sublicense (subject to Section 4.15), under the Biontech  Co-Development Technology to research, have researched, Develop, have Developed, make,  have made, Commercialize and have Commercialized any product in and outside the Field  (excluding any Licensed Product and any Discarded Mixture);   4.7.3 an irrevocable, perpetual, royalty-free, fully paid-up, non- exclusive, non-transferable (except through assignment of this Agreement pursuant to Section  13.4 of the License Agreement as incorporated into this Agreement under Section 11.4),  worldwide license, with the right to sublicense (subject to Section 4.15), under the Sanofi CMC  Technology to research, have researched, Develop, have Developed, make, have made,  Commercialize and have Commercialized products (other than Licensed Products and  Discarded Mixtures) in the field of Intratumoral Administration of any agent for any indication;  4.7.4 a non-exclusive, non-transferable (except through assignment of  this Agreement pursuant to Section 13.4 of the License Agreement as incorporated into this  Agreement under Section 11.4), worldwide, royalty-free license, with the right to sublicense  (subject to Section 4.15), under the Co-Development Background Technology of Biontech to  the extent required: (a) for the Development and Commercialization of Licensed Product #1 in  the Field, and (b) by Sanofi for the co-Development and/or co-Commercialization of any  Sanofi Option Product which constitutes Licensed Product #1 in accordance with the  Development and/or Commercialization agreement concluded in relation to such Sanofi Option  Product under Section 4.2.5 of the License Agreement.    4.7.5 an exclusive, non-transferable (except through assignment of the  this Agreement pursuant to Section 13.4 of the License Agreement as incorporated into this  Agreement under Section 11.4) worldwide license, with the right to sublicense (subject to  Section 4.15), under the Formulation Technology to Develop, have Developed, make, have  made, Commercialize and have Commercialized Licensed Products in the Field; and  4.7.6 an irrevocable, perpetual, royalty-free, fully paid-up, non- exclusive non-transferable (except through assignment of this Agreement pursuant to Section  13.4 of the License Agreement as incorporated into this Agreement under Section 11.4),  worldwide license, with the right to sublicense (subject to Section 4.15) under the Formulation  Technology to research, have researched, Develop, have Developed, make, have made,  Commercialize and have Commercialized mRNA-based products (other than Licensed  Products and Discarded Mixtures) in the field of Intratumoral Administration for any  indication.  

 

Amended & Restated Development Agreement  Execution version  19 4.7.7 In the event BioNTech files any Patent Right covering an [***] formulation that:   (i) [***] and (ii) [***] and (iii) [***] (iv) [***] (v)[***] before a Patent Right within the Formulation Technology publishes, then BioNTech hereby  grants to Sanofi an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive, non- transferable (except through assignment of this Agreement pursuant to Section 13.4 of the  License Agreement as incorporated into this Agreement under Section 11.4), worldwide  license, with the right to sublicense (subject to Section 4.15) under such [***] formulation  Patent Right to research, have researched, Develop, have Developed, make, have made,  Commercialize and have Commercialized DNA-based uses and products. [***] [***] [***] [***] 4.8 For the avoidance of doubt, Background Technology, Joint  Collaboration Technology (other than for the purposes set out in Section 4.3) Biontech  Collaboration Technology (other than for the purposes set out in Section 4.4), Licensed Product  Patents, Sanofi Foreground Technology, Biontech Foreground Technology and Joint  Foreground Technology shall exclude any Co-Development Technology, CMC Technology,  and Formulation Technology, and Section 7.2.3 and the last sentence of Section 7.1 of the  License Agreement shall not apply with respect to any Co-Development Technology, CMC  Technology, or Formulation Technology.   4.9 With respect to the Co-Development Patents and CMC Patents, each  Party shall (a) provide the other Party with written notice reasonably in advance of: (i) any  filing of such Patent Rights for which it controls the Prosecution and Maintenance pursuant  to Section 4.2 above; and (ii) any other substantive submissions and correspondence to  patent office(s) with respect to the Prosecution and Maintenance of such Patent Rights; (b)  provide the other Party with any final drafts of any application for such Patent Right to be  filed or such substantive submission or correspondence (such application, submissions and  correspondence, the Patent Documentation) reasonably in advance of its filing or  submission and consider in good faith the incorporation of reasonable comments by the other  Party thereon; (c) provide the other Party with a copy of all Patent Documentation once it  has been filed or otherwise submitted; (d) provide the other Party with copies of any  substantive communications received from patent office(s) with respect to such Patent  Rights; (e) notify the other Party of any: (i) [***] and (f) provide the other Party with  written notice as early as possible (in any event, no later than [***] prior to abandoning any  such  

 

Amended & Restated Development Agreement  Execution version  20 Patent Rights. Each Party shall cause its employees, agents or consultants, at its expense, to  execute such documents and to take such other actions as reasonably necessary or appropriate  to enable the other Party to prepare, file, Prosecute and Maintain such Patent Rights. In the  event that either Party provides the other Party with the written notice described in clause (f)  prior to abandoning any Patent Rights, then the other Party shall have the option, exercisable  by delivery of written notice thereof within [***] thereafter, to assume the right (but not the  obligation), at its sole expense and sole discretion, to control the Prosecution and  Maintenance of such Patent Right.  4.10 Formulation Patents.  4.10.1 With respect to the Formulation Patents, (i) the Formulation  Priority Application, as well as any Patent Rights filed within [***] of the filing date of the  Formulation Priority Application; and (ii) any Formulation Patent that does not claim  priority to the Formulation Priority Application, [***].  Additionally and also with respect  to Formulation Patents, each Party will (i) provide the other Party’s representative on  the Joint Patent Committee copies of any material communications received from or filed  in patent office(s); (ii) provide the other Party’s representative on the Joint Patent Committee  with drafts of any substantive submissions and correspondence to patent office(s) with respect  to the Prosecution and Maintenance of such Patent Rights reasonably in advance of filing and  consider in good faith the incorporation of reasonable comments by the other Party thereon;  (iii) provide the other Party’s representative on the Joint Patent Committee with copies of any  filed substantive submissions and correspondence to patent office(s) with respect to the  Prosecution and Maintenance of such Patent Rights; (iv) notify the other Party’s  representative on the Joint Patent Committee of [***] (v) notify the other  Party’s representative on the Joint Patent Committee of any intended request for  patent term extension, supplemental protection certification or the like prior to the filing or  submission of such request, which will be reviewed by the Joint Patent Committee before  filing; and (vi) provide the other Party with written notice as early as possible (in any event, no  later than [***] prior to abandoning any such Patent Rights. Each Party shall cause its  employees, agents or consultants, at its expense, to execute such documents and to take  such other actions as reasonably necessary or appropriate to enable the other Party to  prepare, file, Prosecute and Maintain such Patent Rights. In the event that either Party  provides the other Party with the written notice described in clause (vi) prior to abandoning  any Patent Rights, then the other Party shall have the option, exercisable by delivery of  written notice thereof within [***] thereafter, to assume the right (but not the obligation), at its  sole expense and sole discretion, to control the Prosecution and Maintenance of such Patent  Right. Neither Party shall file a terminal disclaimer in connection with a Formulation Patent  without the written consent of the other Party. For clarity, with respect to Formulation  Patents Prosecuted and Maintained by Sanofi pursuant to Section 4.2.3, Sanofi shall have the  sole right (but not the obligation) to (i) use such Patent Rights for patent term  extension (PTE) and supplementary protection certificate (SPC) and (ii) [***]. 4.10.2 The Parties shall [***] share [***] (i) the costs for preparing  and filing (a) the  Formulation Priority Application and any other priority patent  application(s) filed within [***] of the Formulation Priority Application, (b) PCT  application(s) claiming priority to the Formulation Priority Application, and (c) national/ regional stage entries of PCT application(s) claiming priority to the Formulation 

 

Amended & Restated Development Agreement  Execution version  21 Priority Application; and (ii) application filing fees for non-divisional application(s) filed in  non-PCT contracting states that claim priority to the Formulation Priority Application ((i) and  (ii) the Shared Formulation Patent Costs). [***] Sanofi shall have the right (but not the obligation) to file and validate Formulation Patents in additional countries at its costs, in the name of Biontech. Except for the Shared Formulation Patent Costs, Sanofi shall bear the Prosecution and Maintenance costs of Formulation Patents for which it controls Prosecution and Maintenance pursuant to Section 4.2.3 above. Except for the Shared Formulation Patent Costs, Biontech shall bear the Prosecution and Maintenance costs for Formulation Patents for which it controls Prosecution and Maintenance. 4.11 Patent Enforcement    4.11.1 Each Party (Enforcing Party) shall have the first right (but not  the obligation), at its sole discretion, to control the enforcement or otherwise abate the  infringement of any Patent Rights Prosecuted and Maintained by it in accordance with Section  4.2 above. [***]. 4.11.2 [***] 

 

Amended & Restated Development Agreement  Execution version  22 4.12 Each Party shall perform such lawful acts and execute such documents  as requested by the other Party from time to time in order to reasonably assist the other Party  in the Prosecution and Maintenance and enforcement activities described in this Section 4.  4.13 Each Party shall ensure that all employees and other persons acting on  its behalf in performing its obligations under this Agreement shall be obligated, either pursuant  to Applicable Law or pursuant to a binding written agreement, to assign to it, or as it shall  direct, all inventions made or conceived by such employees or other persons.  4.14 No rights or licenses with respect to any Intellectual Property Rights  Controlled by either Party are granted or shall be deemed granted hereunder or in connection  herewith, other than those rights expressly granted in this Agreement or the License Agreement.  4.15 [***]   [***] [***] [***] [***] [***] [***] [***] [***] 4.16 [***]   [***] [***] [***] [***] [***] 

 

Amended & Restated Development Agreement  Execution version  23 [***] [***] [***] [***] [***] 4.17 [***] 5. Profit Sharing. For the avoidance of doubt, the profit sharing within the Biontech Territory pursuant to  Section 4.1.6 of the License Agreement as well as the financial terms (e.g. milestone and  royalty payments) agreed for countries outside the Biontech Territory pursuant to Section 6 of  the License Agreement shall remain unaffected by this Agreement.  6. Governance. 6.1 Project Managers. Each Party shall designate a Development project  manager (Project Manager) to act as its primary contact for all operational matters related to  this Agreement. Each Project Manager shall be responsible for implementing and coordinating  activities hereunder and facilitating the exchange of information between the Parties. Either  Party may replace its Project Manager at any time by informing the other Party’s Project  Manager in advance in writing (which may be by email).  6.2 Joint Project Team. The Parties shall establish a joint project team (the  Joint Project Team) made up of the Project Manager and at least [***] other representatives  from each Party, which shall be responsible for coordinating all activities under this Agreement.  Each Party may replace any of its Joint Project Team representatives upon prior notice to the  other Party.  In particular, the Joint Project Team shall be responsible for:    (a) the review and discussion of the Development Plan and  underlying objectives for Licensed Product #1 in the Field, [***] (b) co-ordinating the implementation of the Development Plan and the associated Budget;  (c) the review and discussion of any proposed amendment or update to the Development Plan, whether during the annual review under Section 2.1.2 or from time  to time during the Term, and the proposal of such amendment or update to the Joint Steering  Committee for approval;  

 

Amended & Restated Development Agreement  Execution version  24 (d) the review and discussion of: (i) the Budget for the applicable period pursuant to the annual review under Section 3.3.1(b), taking into account of any  comments provided by the Joint Financial Committee under Section 6.5.2(b) and the applicable  forecast prepared by the Joint Financial Committee under Section 6.5.2(c); and (ii) any other  proposed amendment to the Binding Budget, and the proposal of each such amended Budget  to the Joint Steering Committee for approval;  (e) the review and approval of any proposed amendment(s) to the Binding Budget with respect to the then-current Calendar Year, provided that such Binding  Budget shall not deviate by [***] or more from the Binding Budget for such Calendar  Year as of the first day of such Calendar Year;   (f) the review and discussion of the proposal by either Party of any modification to the Licensed Product #1 [***] (g) discussion and approval of which party should be responsible for the performance of which Co-Development Activities [***]  (h) discussion and approval of any Third Party proposed to be engaged by a Party to perform or assist with its obligations under this Agreement;  (i) review and discussion of any Co-Development Reports, and discuss and agree whether additional information should be included in future Co-Development  Reports;  (j) oversight of all clinical and regulatory matters with respect to the Licensed Product #1 in the Field;  (k) the preparation and review of all material Regulatory Documentation with respect to the Licensed Product #1 in the Field;  (l) the coordination with the Joint Manufacturing Committee in relation to the CMC Development Plan and the forecasting of Drug Products for Clinical Trials  (as defined in the Clinical Supply Agreement);   (m) discussion and agreement on target product profiles; (n) periodically update the Joint Steering Committee with respect to Co-Development Activities performed and other relevant matters;  (o) facilitating the sharing of data and information between the Parties in relation to the Development activities under the Development Plan, regulatory filings  and regulatory approvals;   (p) discussion and agreement of any alternative timeframe with respect to the discussion of, and submission to the Joint Financial Committee, a proposed  Budget by the Joint Project Team as part of the annual review under Section 3.3.1(b); and  (q) any other responsibilities allocated to the Joint Project Team by the Joint Steering Committee.  

 

Amended & Restated Development Agreement  Execution version  25 6.3 Decisions of the Joint Project Team/Escalation/Joint Steering  Committee.  6.3.1 The quorum for each Joint Project Team meeting shall be at least  one (1) Joint Project Team representative from each Party.  Each Party shall have one collective  vote in all decisions of the Joint Project Team with respect to matters falling within its  responsibility, and shall use good faith efforts to decide such matters unanimously. If consensus  cannot be reached by the Joint Project Team, the relevant matter shall be escalated to the Joint  Steering Committee for discussion and decision.   6.3.2 Each Party hereby acknowledges and agrees that,  notwithstanding the last sentence of Section 11.2.2 of the License Agreement, the Joint  Steering Committee shall be responsible for:   (a) the discussion and agreement of any matter escalated by the Joint Project Team or the Joint Financial Committee under Section 6.3.1 or Section 6.5.3 (as  applicable) for resolution by the Joint Steering Committee;   (b) the discussion and agreement of updates to the Development Plan as part of the annual review under Section 2.1.2 or updates to the Budget as part of annual  review under Section 3.3.1(b) on an annual basis, each such annual update shall be approved  no later than [***] days prior to the end of the relevant Calendar Year;   (c) the discussion and agreement of any other amendment or update to the Development Plan or the Budget, and any amendment or update of the CMC  Development Plan to allocate any CMC Activities for performance by Sanofi as referred by  the Joint Manufacturing Committee under Section 2.8.5;   (d) the discussion and agreement of any modification to the Licensed Product #1 set out in Schedule B;  (e) [***] and (f) the discussion and agreement of any alternative timeframe with respect to the review of, and submission to the Joint Steering Committee of, any updates to a  Development Plan by the Joint Project Team, as part of an annual review under Section 2.1.2, in  the case of (b) to (d), as proposed by the Joint Project Team to the Joint Steering Committee  pursuant to Sections 6.2(c) or Section 6.2(d) (as applicable), or, in the case of (c) and with  respect to the Budget, as proposed by either Party under Section 3.3.2 to reflect the Overspent  Costs in question.    6.3.3 If the Joint Steering Committee cannot agree unanimously on  any matter set out in Sections 6.3.2(a) to (d) (inclusive) and (f):  (a) if such matter constitutes an amendment or update to the then- current Binding Budget, which causes an increase of Biontech’s aggregate share of budgeted  Shared Development Costs with respect to [***] covered by then-current Binding Budget by an  amount equal to [***] or more, the third and fourth sentences of Section 11.2.4 of the  License Agreement and the first two sentences of Section 13.7 of the License Agreement shall  apply (but the last two sentences of Section 13.7 of the License Agreement shall not apply).  If  the Parties’ CEOs are unable to settle any dispute  

 

Amended & Restated Development Agreement  Execution version  26 with respect to such matter escalated to them within thirty (30) days from the date that the  dispute has been escalated to the CEOs, then Sanofi shall have the deciding vote with respect  to such matters; and  (b) otherwise, the third and fourth sentences of Section 11.2.4 of the License Agreement and the last three sentences of Section 13.7 of the License Agreement shall  not apply with respect to such matters, and Sanofi shall have a deciding vote with respect to  such matters (for the avoidance of doubt, without having to escalate such matter to the Parties’  CEOs).  For the avoidance of doubt, any matter set out in Section 6.3.3(a) which is so decided  by the Parties’ CEOs pursuant to Section 13.7 of the License Agreement and any matter set  out in Sections 6.3.3(a) and 6.3.3(b) which is so decided by Sanofi through its exercise of its  deciding vote, shall be treated as having been agreed or approved by the Joint Steering  Committee for the purposes of this Agreement.  6.3.4 If, during each of Calendar Year [***], Sanofi exercises its  final decision-making authority to approve any amendment or update to the Binding  Budget (covering any such Calendar Year) which causes an increase in Biontech’s share of  Shared Development Costs with respect to such Calendar Year (compared with its share of  Shared Development Costs had such amendment or update to the Binding Budget not been  implemented), then Biontech shall not be required to pay to Sanofi the amount of such  increase (the Additional Co-Development Costs) [***] provided that: (i) Biontech shall not  be required to pay more than [***]. 6.3.5 The Joint Project Team shall not have the authority to amend or  modify the terms and conditions of this Agreement or the License Agreement (save for the  amendment of the Development Plan and the Budget in accordance with this Section 6.3) or to  waive any obligation of either Party under this Agreement or the License Agreement.   6.4 Meetings of the Joint Project Team. The Joint Project Team shall meet  no less than once every [***] months, and more often as reasonably considered necessary at  the request of either Party, to, among other matters, provide an update on the progress of the  Development activities hereunder. The Joint Project Team may meet in person or by means of  teleconference, internet conference, videoconference or other similar communications  equipment, provided that at least [***] meeting shall be conducted in person in each Calendar  Year. Minutes of all meetings of the Joint Project Team shall be prepared by or on behalf of  such representative of the Joint Project Team of either Party as the Joint Project Team may  

 

Amended & Restated Development Agreement  Execution version  27 from time to time agree and shall be transmitted by such representative of such Party to all  members of the Joint Project Team within [***] days after the date of the meeting. The  minutes shall be deemed to be approved by the other Party if the other Party does not object  within [***] days of receipt.  6.5 Joint Financial Committee.   6.5.1 Each Party shall designate [***] representatives which  together shall constitute the joint financial committee (Joint Financial Committee). Each Party  may replace any of its Joint Financial Committee representatives upon prior notice to the other  Party.  6.5.2 The Joint Financial Committee shall be responsible for:  (a) review and approval of any reconciliation report as requested by Biontech under Section 3.3.4(b);    (b) review of the proposed Budget submitted by the Joint Project Team under Section 3.3.1(b), and submission of any comments to the Joint Project Team with  respect to such proposed Budget within [***] of its receipt of the proposed Budget from the  Joint Project Team;   (c) during each Calendar Quarter, preparation of a forecast of Shared Development Costs reasonably expected to be incurred by each Party with respect to  the immediately subsequent Calendar Quarter; and  (d) preparation of necessary documentation to support strategic financial decisions of the Joint Steering Committee in connection with the Development Plan.   6.5.3 The quorum for each Joint Financial Committee meeting shall  be at least one (1) representative from each Party.  Each Party shall have one collective vote in  all decisions of the Joint Financial Committee with respect to matters falling within its  responsibility, and shall use good faith efforts to decide all such matters unanimously. If  consensus cannot be reached by the Joint Financial Committee, the relevant matter shall be  escalated to the Joint Steering Committee for discussion and decision.  If the Joint Steering  Committee cannot agree on such matter unanimously, the third sentence of Section 11.2.4 (and  accordingly Section 13.7) of the License Agreement shall apply with respect to such matter  accordingly, except that, the reference to “Parties’ CEOs” in Section 13.7 shall instead be  deemed to be a reference to Biontech’s CEO and Sanofi’s Chief Financial Officer with respect  to such matter, and any such matter to the extent approved or agreed by the Joint Steering  Committee or Biontech’s CEO and Sanofi’s Chief Financial Officer under Section 13.7 of the  License Agreement (as applicable) shall be treated as having been agreed or approved by the  Joint Financial Committee for the purposes of this Agreement.  The Joint Financial Committee  shall not have the authority to amend or modify the terms and conditions of this Agreement or  the License Agreement or to waive any obligation of either Party under this Agreement or the  License Agreement.   6.6 Joint Patent Committee  6.6.1 Each Party shall designate [***] shall constitute the joint patent  committee (Joint Patent Committee). Each Party may replace its Joint Patent Committee  [***] upon notice to the other Party.  

 

Amended & Restated Development Agreement  Execution version  28 6.6.2 The Joint Patent Committee shall be responsible for:  (a) review and approval of Prosecution and Maintenance decisions regarding Formulation Patents as per Section 4.10.1;    (b) review and approval of Patent Documentation related to Formulation Patents as per Section 4.10.1;  (c) reconciliation of Shared Formulation Patent Costs. 6.6.3 [***]  7. Pharmacovigilance and Regulatory Matters. 7.1 Regulatory Matters. Sanofi or its Affiliate shall have the exclusive right (but not the obligation) to file, submit and maintain any Regulatory Documentation in its name  (and such Regulatory Documentation, to the extent filed by Sanofi or its Affiliate, shall be the  sole property of Sanofi (or its Affiliate, as applicable)), unless otherwise agreed between the  Parties.  Without limiting the foregoing, Sanofi or its Affiliate shall be the holder of the  Marketing Approval for any Licensed Product #1 in the Field to the extent the relevant  applications have been filed by Sanofi or its Affiliate. Sanofi shall lead all interactions with all  Regulatory Authorities in all regions. [***] Biontech shall have the right (but not the obligation) to participate in and attend with Sanofi  (with not less than two representatives from Biontech) all meetings with Regulatory Authorities  in the Biontech Territory, to the extent permitted by the relevant Regulatory Authority and  Applicable Law.   

 

Amended & Restated Development Agreement  Execution version  29 7.2 Pharmacovigilance. To the extent Sanofi or its Affiliate is the sponsor  of a clinical trial with respect to a Licensed Product #1 in the Field, Sanofi or its Affiliate shall  be the host of the clinical and pharmacovigilance related databases with respect to such clinical  trial and shall be responsible for compliance with all Applicable Laws pertaining to the safety  of such Licensed Product #1.  Each Party shall comply with its respective obligations under the  Safety Data Exchange Agreement entered into between the Parties dated October 4, 2018  (SDEA). For the avoidance of doubt, such agreement shall constitute a “SDEA” under Section  3.2.3 of the License Agreement.   8. Confidentiality and Data Privacy 8.1 For the avoidance of doubt: (a) any information disclosed by one Party to the other Party pursuant to this Agreement (including through any audit or inspection  conducted pursuant to this Agreement or during any meeting of the Joint Project Team, Joint  Steering Committee, Joint Manufacturing Committee or the Joint Financial Committee) shall  constitute information related to the subject matter of the License Agreement for the purposes  of the definition of “Confidential Information” under the License Agreement, and the  provisions in such definition and Section 8 of the License Agreement shall apply to such  information accordingly; and (b) the Sanofi Co-Development Technology, Co-Development  Background Technology of Sanofi, Regulatory Documentation filed by Sanofi or its Affiliate  and Clinical Data shall constitute Sanofi’s Confidential Information (in respect of which Sanofi  is the Disclosing Party and Biontech the Receiving Party) and the Biontech Co-Development  Technology, CMC Technology and Co-Development Background Technology of Biontech  shall constitute Biontech’s Confidential Information (in respect of which Biontech is the  Disclosing Party and Sanofi the Receiving Party).  8.2 Notwithstanding any other term of this Agreement, neither Party shall,  or shall be required to, transfer to the other Party, any personal data if either Party, acting  reasonably, determines that such transfer or any subsequent processing of such personal data  would not comply with any Applicable Laws relating to the transfer and processing of such  personal data.  Each Party shall ensure that any transfer and subsequent processing of such  personal data by it under or in connection with this Agreement is lawful, and if required the  Parties shall negotiate in good faith and seek to enter into such agreements as are reasonably  required to ensure the same, including, where applicable, entering into the Standard Contractual  Clauses published by the European Commission. For the purposes of this Section 8.2, “personal  data” and “process” shall be construed in accordance with the EU General Data Protection  Regulation 2016/679.   9. Term and Termination. 9.1 Term. This Agreement shall be effective from the Effective Amendment Date and shall continue until the completion of all Co-Development Activities and CMC  Activities, unless terminated earlier in accordance with Section 9.2 or otherwise agreed  between the Parties (the Term).    9.2 Termination.   9.2.1 This Agreement shall terminate automatically:  (a) in the event of any termination or expiry of the License Agreement in its entirety;   

 

Amended & Restated Development Agreement  Execution version  30 (b) in the event of any termination of the License Agreement on a Licensed Product-by-Licensed Product basis, where such Licensed Product is Licensed  Product #1, under Section 12.3.1 or Section 12.3.2 of the License Agreement; or  (c) in the event of any termination of the Co-Development of an Option Product under Section 12.2.2 or Section 12.3.4 of the License Agreement, where such  Option Product is Licensed Product #1.  9.2.2 Either Party may terminate this Agreement with immediate  effect by written notice to the other Party:  (a) if the other Party materially breaches any of its material obligations hereunder and fails to cure such breach [***] following its receipt of written notice  thereof from the first Party. In the event of a dispute between the Parties as to whether a  material breach has occurred, either Party may refer such dispute to the dispute resolution  process set out in Section 13.7 of the License Agreement.  Any right to terminate under this  Section 9.2.2(a) or Section 12.3.4 of the License Agreement and the cure period shall be  suspended in the event that, during the cure period, the Party alleged to have been in material  breach shall have in good faith initiated dispute resolution in accordance with Section 13.7 of  the License Agreement with respect to the alleged breach, which suspension shall continue  until such dispute has been resolved in accordance with Section 13.7 of the License Agreement;  or   (b) if the other Party breaches its payment obligations under this Agreement with respect to an aggregate outstanding amount of at least [***] and such Party  fails to cure such breach within [***] following its receipt of written notice thereof from the  first Party.   9.3 Consequences of Termination or Expiry.  9.3.1 General consequences.   (a) In the event of any termination or expiry of this Agreement: (i) within [***] days of such termination or expiry, each Party shall return or deliver to the other Party all of the other Party’s Confidential  Information disclosed to such Party under this Agreement, as well as any of the other Party’s  materials delivered by the other Party under this Agreement, provided that each Party shall be  permitted to retain and use any Confidential Information of the other Party which is necessary  or useful for such Party to exercise any remaining rights or perform its remaining obligations  under this Agreement or under the License Agreement; and  (ii) within [***] days of such termination or expiry, the  Parties shall reconcile the Shared Development Costs incurred prior to the date of such  termination or expiry (to the extent not previously reconciled under Section 3.3.4), in  accordance with the principles set out in Sections 3.1 and 3.2, and shall promptly make any  required payments to the other Party as a result of such reconciliation.  Except as set forth in  Sections 9.3.2(a)(iii) and 9.3.2(c), any Additional Co-Development Costs, to the extent not  already paid by Biontech as of the date of such termination or expiry, shall become immediately  payable by Biontech.  9.3.2 Specific consequences.  

 

Amended & Restated Development Agreement  Execution version  31 (a) In the event of any termination of this Agreement as a result of Sanofi’s termination of the entirety of the License Agreement under Section 12.2.1  (Termination by Sanofi for convenience) of the License Agreement, in addition to the  termination events set out in Section 12.4.2 of the License Agreement:  (i) at Biontech’s written request, Sanofi shall: (1) transfer control to Biontech of any ongoing clinical trial being conducted by or on behalf of Sanofi  under the Development Plan as of the effective date of termination and (2) continue to conduct  such clinical trial (the costs of which as between the Parties, and the invoicing and  reconciliation of such costs, shall continue to be governed by Section 3), for up to [***]  months to enable such transfer to be completed without interruption of any such clinical trial,  whereupon after such transfer Biontech will assume the costs of such clinical trial, provided  that, with respect to any such clinical trial for which such transfer is expressly prohibited by  the applicable Regulatory Authority, Sanofi shall continue to conduct such clinical trial to  completion, at Sanofi’s cost and expense;   (ii) the licenses granted to Biontech under Section 4.6 of this Agreement shall survive; and  (iii) for any Additional Co-Development Costs, to the extent not already paid by Biontech as of the date of such termination, the payment schedule  pursuant to Section 6.3.4 shall continue to apply.  (b) In the event of any termination of this Agreement as a result of Biontech’s termination of co-Development of Licensed Product #1 under Section 12.2.2  (Termination of co-development by Biontech for convenience) of the License Agreement, for  the avoidance of doubt, (i) the termination consequences set forth in Section 12.4.4 of the  License Agreement shall apply; and (ii) the licenses granted to Sanofi under Sections 7.3.1 and  7.3.3(ii) of the License Agreement and under Section 4.7 of this Agreement shall survive.  (c) In the event of any termination of this Agreement as a result of Biontech’s termination of the License Agreement under Section 12.3.1 (Termination for  Sanofi’s breach) or Section 12.3.3 (Termination for Sanofi’s insolvency) of the License  Agreement, whether in its entirety or with respect to Licensed Product #1 only, in addition to  the termination events set out in Section 12.4.6 of the License Agreement, (1) Section  9.3.2(a)(i) of this Agreement shall apply with respect to any ongoing clinical trial conducted  by or on behalf of Sanofi under the Development Plan as of the effective date of such  termination; (2) the Clinical Supply Agreement shall automatically terminate with respect to  Licensed Product #1 (and such termination shall be treated as a termination by Sanofi pursuant  to Section 12.3(c) of the Clinical Supply Agreement); (3) the licenses granted to Biontech under  Section 4.6 of this Agreement shall survive; and (4) for any Additional Co-Development Costs,  to the extent not already paid by Biontech as of the date of such termination, the payment  schedule pursuant to Section 6.3.4 shall continue to apply.  (d) In the event of any termination of this Agreement as a result of Sanofi’s termination of the License Agreement under Section 12.3.2 (termination for  Biontech’s breach) or Section 12.3.3 (termination for Biontech’s insolvency) of the License  Agreement (whether in its entirety or with respect to Licensed Product #1 only), in addition to  the termination events set out in Section 12.4.8 of the License Agreement:  (i) within [***] after such date of termination, Biontech shall provide to Sanofi a report containing the details set out in Section 2.5(a) to (d)  

 

Amended & Restated Development Agreement  Execution version  32 with respect to the Co-Development Activities performed by or on behalf of Biontech prior to  the date of such termination, to the extent not previously reported to Sanofi under Section 2.5;  (ii) promptly upon Sanofi’s request: (1) Biontech shall assign (or, in the case of agreements relating to Licensed Product #1 and other products being  Developed or Commercialized by Biontech, partially assign) to Sanofi, to the extent assignable  (or partially assignable, as applicable), Biontech’s rights in any or all agreements with  Biontech’s Approved Co-Development Third Parties to the extent related to the Co- Development Activities; and (2) Biontech shall provide copies of such agreements to Sanofi.  To the extent that any such agreement is not assignable (or partially assignable, as applicable)  by Biontech, then such agreement shall not be assigned (or partially assigned, as applicable),  and upon the request of Sanofi, Biontech shall cooperate with Sanofi in good faith and allow  Sanofi to obtain and to enjoy the benefit of such agreement (or, in the case of any agreement  relating to Licensed Product #1 and other products being Developed or Commercialized by  Biontech, such agreement to the extent relating to Licensed Product #1) in the form of a license  or such other rights;  (iii) to the extent the Manufacturing process with respect to Licensed Product #1 has not completely transferred to Sanofi pursuant to Section 3.3.4 of the  License Agreement, at Sanofi’s request: (1) Biontech shall transfer such Manufacturing process  to Sanofi or its designee or (2) continue to supply to Sanofi with clinical quantities of Licensed  Product #1 in the Field subject to a supply agreement to be negotiated and agreed in good faith  between the Parties, until the earlier of: (i) [***] after the effective date of termination; or (ii)  such Manufacturing process having been completely transferred to Sanofi, or establishment by  Sanofi of an alternative supply for such Licensed Product on commercially reasonable terms;  and   (iv) Biontech shall, at Sanofi's written request, (a) transfer control to Sanofi of any ongoing clinical trial being conducted by or on behalf of Biontech  under the Development Plan as of the effective date of termination and (b) continue to conduct  such clinical trials, at Biontech’s cost in the case of termination of the License Agreement under  Section 12.3.2 (termination for Biontech’s breach) of the License Agreement, and at Sanofi’s  cost in the case of  termination under Section 12.3.3 (termination for Biontech’s insolvency)  of the License Agreement in the case of, for up to [***] to enable such transfer to be  completed without interruption of any such clinical trial, whereupon after such transfer Sanofi  will assume the costs of such clinical trial, provided that, with respect to any such clinical trial  for which such transfer is expressly prohibited by the applicable Regulatory Authority,  Biontech shall continue to conduct such clinical trial to completion, at Biontech’s cost and  expense;  (e) In the event of any termination of this Agreement as a result of Sanofi’s termination of the co-Development of Licensed Product #1 under Section 12.3.4  (termination for Biontech’s breach of co-development obligations) of the License Agreement  or any termination by Sanofi of this Agreement under Section 9.2.2, for the avoidance of doubt,  Section 12.4.9 of the License Agreement shall apply, and the following provisions shall apply  in addition:  (i) Biontech shall grant to Sanofi: (a) an exclusive, transferable, worldwide license, with the right to sublicense (subject to Section 7.3.4 of the  License Agreement), under the Biontech Background Technology in Schedule D of the License  Agreement, Biontech’s interest in the Joint Collaboration Technology (if any), Biontech Co- Development Technology and Biontech Foreground Technology to Develop, have Developed,  

 

Amended & Restated Development Agreement  Execution version  33 make, have made, Commercialize and have Commercialized Licensed Product #1 in the Field;  and (b) a non-exclusive, transferable, worldwide license, with the rights to sublicense (subject  to Section 7.3.4 of the License Agreement), under the Biontech Background Technology (to  the extent not set out in Schedule D of the License Agreement) to Develop, have Developed,  make, have made, Commercialize and have Commercialized Licensed Product #1 in the Field.  For the avoidance of doubt, the foregoing licenses shall not limit Section 7.3 of the License  Agreement, and shall not be affected by any termination of the License Agreement (whether in  its entirety or with respect to a product).  For the purposes of Section 7.3.4(a) of the License  Agreement, the phrase “the rights granted to such Party pursuant to Section 7.3.1 to 7.3.3” shall  be deemed to also include the rights granted to Sanofi under this Section 9.3.2(e)(i), and for  the purposes of Section 7.3.4(b) of the License Agreement, the phrase “the rights granted to it  under Section 7.3.1(b) or 7.3.2(b)” shall be deemed to also include rights granted to Sanofi  under this Section 9.3.2(e)(i);    (ii) the licenses granted to Sanofi under Section 4.7 shall survive;  (iii) Biontech shall no longer have the right to co-Develop or co-Commercialize Licensed Product #1;   (iv) any milestones payable by Sanofi pursuant to Section 6 of the License Agreement with respect to Licensed Product #1 shall be reduced by [***] and  any royalties payable by Sanofi pursuant to Section 6 of the License Agreement to the  extent relating to the Net Sales of Licensed Product #1 shall be reduced by [***] and  (v) the events set out in Section 9.3.2(d)(i) to (iv) shall apply. 9.3.3 Survival.  Upon the expiry or termination of this Agreement, the  provisions of this Agreement shall no longer be of any force or effect, save for the following  provisions which shall survive such expiry or termination: Sections 1, 2.6.1 (for the duration  set out therein), 2.7 (first sentence), 4 (in accordance with Sections 4.16 and 9.3.2), 8.1, 9.3, 10  and 11 (including the Sections of the License Agreement as incorporated into this Agreement  under Section 11.4).  10. Disclaimer of Warranties; Limitation of Liability 10.1 For the avoidance of doubt, the Co-Development Activities constitute Development to be conducted under the License Agreement, and accordingly the provisions of  Section 9.3 of the License Agreement shall apply accordingly.  10.2 For the avoidance of doubt, Section 10.3 of the License Agreement shall  also apply with respect to this Agreement.   11. General Provisions. 11.1 This Agreement shall be governed by the laws of Germany without reference to its conflict of laws provision. Any dispute arising out of this Agreement shall be  constitute a dispute arising between the Parties in connection with the License Agreement, and  accordingly Section 13.7 and the second, third and fourth sentences of Section 13.8 of the  License Agreement shall apply to any such dispute, subject to Sections 2.8.5, 6.3 and 6.5.3.  

 

Amended & Restated Development Agreement  Execution version  34 11.2 This Agreement (including the Schedules to this Agreement), together  with the License Agreement and the Clinical Supply Agreement, represent the entire  understanding between the Parties with respect to the subject matter hereof and supersedes all  previous oral or written communication or agreements, and all contemporaneous oral  communication and agreements between the Parties. Each Party acknowledges and agrees that,  if there is any conflict between any provision of this Agreement and any provision of the  License Agreement or the Clinical Supply Agreement, such provision of this Agreement shall  prevail to the extent of such conflict.  11.3 This Agreement many only be amended, modified or supplemented by  the Parties in writing. The same applies to this Section 11.3.  11.4 Sections 13.1, 13.4, 13.5, 13.6, 13.9 and 13.10 of the License Agreement  shall be incorporated by reference into this Agreement (and any reference to “this Agreement”  in each such incorporated provision shall be construed as a reference to this Agreement).  [Signatures on the Following Page]  

 

Amended & Restated Development Agreement  Execution version  35 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly  authorized representatives.  SANOFI  Dr. Sierk Poetting,  Managing Director   By: _________________________________  /s/ Alban de La SablièreBy: _________________________________  Alban de La Sablière,  Head of Sanofi Partnering  BIONTECH RNA PHARMACEUTICALS GMBH  /s/ Dr. Sierk Poetting /s/ lban de La Sablière /s/ Dr. Sierk Poetting 

 

Development Agreement  Schedule A  36  Schedule A - Approved Co-Development Third Parties  Approved Co-Development Third Parties of Sanofi:  Approved Co-Development Third Parties of Biontech:  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule A  37  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule B  38  Schedule B –Licensed Product #1  SAR441000 - A Mixture containing the following:    mRNA encoding Interferon alpha   mRNA encoding IL12   mRNA encoding IL15sushi   mRNA encoding GM-CSF  

 

Development Agreement  Schedule C  39  Schedule C – Development Plan  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement Schedule C 40 Dose Escalation Phase Monotherapy SAR441000 lntratumorally Dose in μg, Weekly  All Solid Tumors (n = 20-38)  Accelerated  Escalation (n=2)  DL1  8 μg  DL2  24 μg  DLJ  72 μg  Escalation with Overdose Control (EWOC) (n=18-36)  DL4  200μg  DL5  500μg  DL6  100Cμg  DL7  2000μg  DL8  400Cμg  Dose Escalation Phase Combination (-18-36)  Adaptive Bayesian Dose Escalation  DLX  SAR441000 lntratumorally□ose in μg, Weekly  Cemlpllmab IV 350 mg Q3W  DLX  MTD /  MAD'  Expansion Phase Monotherapy  Advanced Melanoma after failure to anti·PD-1/PD-L 1 (n=34)  First 16 patients  MTD  Interim  Expansion Phase: Combination• (n=156)  SAR441000 lntratumorally at RD Dose in μg, Weekly  +  Cemiplimab IV 350 mg Q3W  Cohort A (n=40)  Melanoma PD· 1 failure  Cohort B (n=28)  Melanoma PD-1 m11ve  CohortC (n•29)  CSCCnaive  Cohort D (n=~9)  HNSCC PD-1 narve  First 26 patients  Interim  First 14 patients  Interim  First 10 patients  Interim  First 26 patients  Interim  'Simon's two-stage design: 1-sided alpha of 5% with 85% power  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  41  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  42  PRB'.:LINICAL PHASE  PRB'.:LINICAL CEVB.OPMENT  PHASE 01  RH SING.EACENT & Combo STlDY  BJ PEIJIATRC INVESflGATKJNAL PLAN  HA INTBlACTlONS  Melanoma • 2 L • Sn gle Agent  PHASE 213  PHASE213 sruov  D\TA POOLING& ASSESSIIBIT  JOlCIQTY SfUIJES RlR SI.IIMSSION  US PEIJIATRC STUDY PLAN  SUBMISSION - APPROVAL  BJAJS SI.IIMSSCIN PREPARATCIN  US REIJSfRATION PROCEDURE  BJ REIJSfRATION PROCBJURE  -.  PHASE 213  HA INTBlACTlON S RlR Ca..K>  PHASE213 sruov  D\TA POOLING& ASSESSIIBIT  SUBMISSION - APPROVAL  BJAJS SI.IIMSSCIN PREPARATCIN  US REIJSfRATION PROCEDURE  BJ REIJSfRATION PROCBJURE  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  43  -- -- -- -- -- -- -- -- -- -- -- -- -- ~- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- - 1 I I I I I I I  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  44  FPI combo  1► Nov25  POC mono/ GNG Ph3 mono  ► Jul2021  POC combo/ GNG Ph3 combo  1► Jan2022  2019 2020 2021 2022 2023 2024 2025 2026  Jan 2019 ---------------~M=on= ot=h•=ra,,..,_. _______________ May 2025  - Escalation E xpans1oniP 1vota I  ~   ~ ~  ~ "ongoing TE015297 Phase 1 study  .. ~ ..  Subf sion  I funded  FPI----..... LPI IL~FPl-=:===-l~P~LV~C~•·~· P~a~rt_Jlr =~~~=7 I Notlunded  CSCC: CUlaneous Squamous Cel GarcCloma; HNSCC: Head & Neel< ~ous Cell  ~~-:;(!-:': FtrStllasl Patient; GNG: ~ decision POOl~ LPI.V: last  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  45  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  46  B  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  47  8  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  48  8  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  49  .r  8  8  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  50  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule C  51  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule D  52  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule D  53  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

Development Agreement  Schedule D  54  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

 

55  Schedule E – [***] Formulation for SAR441000  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]a6aalexandriarealestatet

Copyright © 2012.  Alexandria Real Estate Equities, Inc.  ALL  RIGHTS RESERVED.  Confidential and Proprietary.  Do Not Copy  or Distribute.  Alexandria and Alexandria Logo are registered  trademarks of Alexandria Real Estate Equities, Inc.  52809836-v4  SIXTH AMENDMENT TO LEASE AGREEMENT  THIS SIXTH AMENDMENT TO LEASE AGREEMENT (this “Sixth Amendment”) is dated  August 2, 2021 and hereby effective as of August 4, 2021 (“Effective Date”), between TECH PARK 270  III, LLC, a Maryland limited liability company, having an address at 26 North Euclid Avenue, Pasadena,  California  91101 (“Landlord”), and BIONTECH US INC., a Delaware corporation, having an address at  Suite 110, 40 Erie Street, Cambridge, Massachusetts  02139 (“Tenant”).   RECITALS  A. Landlord and Kite Pharma, Inc., a Delaware corporation (“Kite”), have entered into that certain Lease Agreement (“Original Lease”) dated as of December 1, 2017, as amended and/or affected  by that certain First Amendment to Lease Agreement dated January 29, 2018 (“First Amendment”), that  certain Second Amendment to Lease Agreement dated February 26, 2018 (“Second Amendment”), that  certain Third Amendment to Lease Agreement dated September 24, 2018 (“Third Amendment”) that  certain Fourth Amendment to Lease Agreement dated May 23, 2019 (“Fourth Amendment”), that certain  Fifth Amendment to Lease Agreement dated July 7, 2020 (“Fifth Amendment”), that certain Expansion  Premises Work Letter dated July 7, 2020 (“Work Letter”), that certain letter agreement dated June 23,  2020 (the “June Letter Agreement”), that certain letter agreement dated July 23, 2020 (“July Letter  Agreement”), and that certain that certain Acknowledgement of Commencement Date dated December 7,  2017 (“Acknowledgment of Commencement Date” and, together with the Original Lease, the First  Amendment, the Second Amendment, the Third Amendment, the Fourth Amendment, the Fifth  Amendment, the Work Letter, the June Letter Agreement and the July Letter Agreement, the “Lease”),  wherein Landlord leased to Tenant approximately [***] rentable square feet (“Premises”) located at Suite 200,  930 Clopper Road, Gaithersburg, Maryland  20878-1301, as more particularly described in the Lease.  B. Landlord, Kite, and Tenant entered into that certain Consent to Assignment dated as of August 2, 2021 (“Consent”) wherein Landlord consented to the assignment of the Lease from Kite to  Tenant since such assignment was not a Permitted Assignment.  C. Landlord and Tenant desire to amend the Lease, among other things, to extend the Base Term for a period of 34 months from the current expiration date of September 30, 2030 to July 31, 2033.  AGREEMENT  NOW, THEREFORE, in consideration of the foregoing Recitals, the mutual promises and  conditions contained herein, and for other good and valuable consideration, the receipt and legal sufficiency  of which are hereby acknowledged, Landlord and Tenant hereby agree that the Lease is amended as  follows:  1. Definitions; Recitals.  Terms used in this Sixth Amendment but not otherwise defined shall have the meanings set forth in the Lease.  The Recitals form an integral part of this Sixth Amendment  and are hereby incorporated by reference.  2. First Extension Term.  The Base Term expires at midnight on September 30, 2030.  The Base Term is hereby extended, such that it shall run for an additional period (“First Extension Term”)  beginning on October 1, 2030 and, unless earlier terminated or extended in accordance with the terms and  conditions of the Lease, expiring 34 months thereafter (i.e., July 31, 2033). For purposes of the Lease,  “Term” shall mean, collectively, the Base Term and the First Extension Term.   3. Base Rent for First Extension Term.  During the First Extension Term, the Base Rent for the Premises shall be increased on each anniversary of the Adjustment Date (i.e., October 1 of each year)),  ~  A L E X A N D R I A.  THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN  EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE  COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Exhibit 4.62 

 

Sixth Amendment to Lease Agreement – BioNTech US Inc. Page - 2  Suite 200, 930 Clopper Road, Gaithersburg, Maryland    Copyright © 2012.  Alexandria Real Estate Equities, Inc.  ALL  RIGHTS RESERVED.  Confidential and Proprietary.  Do Not Copy  or Distribute.  Alexandria and Alexandria Logo are registered  trademarks of Alexandria Real Estate Equities, Inc.  52809836-v4  by multiplying the monthly Base Rent payable immediately before such Adjustment Date by the Rent  Adjustment Percentage (i.e., [***]%) and adding the resulting amount to the monthly Base Rent  payable immediately before such Adjustment Date, as set forth in Section 4 of the Lease.  The Parties  acknowledge that the first Adjustment Date after the Effective Date shall occur on October 1, 2021.  Base  Rent, as so adjusted, shall thereafter be due as provided in Section 4 of the Lease.  4. Amendment to Basic Lease Provisions (Tenant’s Notice Address).  Tenant’s Notice Address under the Lease is hereby changed to the following:  Tenant’s Notice Address:  [***] [***] [***] [***] With copies via e-mail to:  [***] [***] [***]  5. Identification Signage.  Notwithstanding any contrary provision contained in  Section 38(b) of the Lease, Tenant shall have the right to install and affix the Identification Signage on the  façade of the Building facing Clopper Road subject to the terms and conditions as more fully set forth in  Section 38(b) of the Lease.  6. [***]  7. Roof Equipment.  Notwithstanding any contrary provision contained in Section 41 of the  Lease, Tenant shall have the right (and, where applicable, the obligation) to install, maintain, and remove  the Roof Equipment on the top of the roof the Building subject to the terms and conditions as more fully set  forth in Section 41 of the Lease.  8. Landlord Representations.  Landlord represents and warrants to Tenant that (i) the  Lease, as amended by this Sixth Amendment, represents the entire agreement between Landlord and  Tenant and there are no further or other instruments or agreements, written or verbal, between Landlord  and Tenant regarding the lease of the Premises, (ii) Tenant is not in default pursuant to the terms of the  Lease, and to Landlord’s Knowledge (as defined below), no event has occurred that, with the passage of  time, or the giving of notice, or both, would constitute a default by Tenant under the Lease, (iii) both the  Commencement Date and the Expansion Premises Commencement Date have occurred; (iv) [***].  For  purposes of this paragraph, “Landlord’s Knowledge” means the current actual knowledge after  reasonable inquiry of Lawrence J. Diamond, Co-Chief Operating Officer of Alexandria Real Estate Equities,  Inc.  In no event whatsoever shall Mr. Diamond have any personal liability under this Sixth Amendment.  ~  A L E X A N D R I A.  

 

Sixth Amendment to Lease Agreement – BioNTech US Inc. Page - 3  Suite 200, 930 Clopper Road, Gaithersburg, Maryland    Copyright © 2012.  Alexandria Real Estate Equities, Inc.  ALL  RIGHTS RESERVED.  Confidential and Proprietary.  Do Not Copy  or Distribute.  Alexandria and Alexandria Logo are registered  trademarks of Alexandria Real Estate Equities, Inc.  52809836-v4  9. Miscellaneous. a. This Sixth Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and  discussions.  This Sixth Amendment may be amended only by an agreement in writing, signed by the  parties hereto.  b. This Sixth Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries,  affiliates, assigns, heirs, successors in interest and shareholders.  c. This Sixth Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature  process complying with the U.S. federal ESIGN Act of 2000), or other transmission method and any  counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective  for all purposes.  Electronic signatures shall be deemed original signatures for purposes of this Sixth  Amendment and all matters related thereto, with such electronic signatures having the same legal effect as  original signatures.  d. Tenant and Landlord represents and warrants to the other  that neither has dealt with any broker, agent, or other person (collectively, “Broker”) in connection with this Sixth Amendment  and that no Broker brought about this transaction by or through the actions of such party.  Landlord and  Tenant hereby agrees to indemnify and hold each other harmless from and against any claims by any  Broker claiming a commission or other form of compensation by virtue of having dealt with either Landlord  or Tenant, respectively, with regard to this Sixth Amendment.  e. Except as amended and/or modified by this Sixth Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and  unchanged by this Sixth Amendment.  In the event of any conflict between the provisions of this Sixth  Amendment and the provisions of the Lease, the provisions of this Sixth Amendment shall prevail.   Regardless of whether specifically amended by this Sixth Amendment, all of the terms and provisions of  the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Sixth  Amendment.  All references in the Lease to the “Lease” shall be deemed to be a reference to the Lease as  amended by this Sixth Amendment.  [SIGNATURES APPEAR ON NEXT PAGE]  ~  A L E X A N D R I A.  

 

Sixth Amendment to Lease Agreement – BioNTech US Inc. Page - 4  Suite 200, 930 Clopper Road, Gaithersburg, Maryland    Copyright © 2012.  Alexandria Real Estate Equities, Inc.  ALL  RIGHTS RESERVED.  Confidential and Proprietary.  Do Not Copy  or Distribute.  Alexandria and Alexandria Logo are registered  trademarks of Alexandria Real Estate Equities, Inc.  IN WITNESS WHEREOF, the parties hereto have executed this Sixth Amendment under seal as  of the day and year first above written.  TENANT:  BIONTECH US INC.,  a Delaware corporation  By:___________________________(SEAL)  Name: Richard Gaynor  Title: President  LANDLORD:  TECH PARK 270 III, LLC,   a Maryland limited liability company  By: ARE-MM Tech Park 270 III, LLC,  a Delaware limited liability company,  managing member  By: ARE-930 Clopper Road, LLC,  a Delaware limited liability company,  managing member  By: Alexandria Real Estate Equities, L.P.,  a Delaware limited partnership,  managing member  By: ARE-QRS CORP.,  a Maryland corporation,   general partner  By:_____________________(SEAL)  Name:________________________  Title:__________________________  DocuSign Envelope ID: B29A6BEF-9DEB-4DB1-A37C-A283E6F2CBA0 CD  A L E X A N D R I A,  /s/ Richard Gaynor 

 

DocuSign Envelope ID: B29A6BEF-9DEB-4DB1-A37C-A283E6F2CBA0  Sixth Amendment to Lease Agreement- BioNTech US Inc.  Suite 200, 930 Clopper Road, Gaithersburg, Maryland  Page - 4  IN WITNESS WHEREOF, the parties hereto have executed this Sixth Amendment under seal as  of the day and year first above written.  TENANT: BIONTECH US INC.,  a Delaware corporation  By: (SEAL)  Name: Richard Gaynor  Title: President  LANDLORD: TECH PARK 270 Ill, LLC,  a Maryland limited liability company  By: ARE-MM Tech Park 270 Ill, LLC,  a Delaware limited liability company,  managing member  By: ARE-930 Clopper Road, LLC,  a Delaware limited liability company,  managing member  By: Alexandria Real Estate Equities, LP.,  a Delaware limited partnership,  managing member  All.II. J\u' ITJJ □l □  By:  Copyright © 2012. Alexandria Real Estate Equities, Inc. ALL  RIGHTS RESERVED. Confidential and Proprietary. Do Not Copy  or Distribute. Alexandria and Alexandria Logo are registered  trademarks of Alexandria Real Estate Equities, lnc.  /s/ Richard Gaynor  ARE-QRS CORP.,  a Maryland corporation,   general partner  By:_____________________(SEAL)  Name:________________________  Title:__________________________  /s/ Gregory Kay Gregory Kay Senior Vice President Real Estate Legal Affairs

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]